Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2024

Filing Date
Filed February 18, 2025
Period End
December 31, 2024
Security
HALO
One revenue dollarkept$0.44
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-K filed February 18, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,015,324 thousanda ($1.02 billion) for 2024, up from $829,253 thousand in 2023.

Royalties were $570,991 thousandb, product sales, net were $303,492 thousand, and revenues under collaborative agreements were $140,841 thousand. Net income rose to $444,091 thousand from $281,594 thousand, and diluted EPS was $3.43 versus $2.10. ENHANZE, the company's rHuPH20-based subcutaneous drug delivery technology, is the largest revenue driver, and the company has eleven collaborations with nine currently approved partner products.

The balance sheet at December 31, 2024 showed cash, cash equivalents and marketable securities of $596.1 millionc, against consolidated debt carrying value of $1,505.8 million, including $805.0 million of 0.25% convertible notes due 2027 and $720.0 million of 1.00% convertible notes due 2028. Management states these resources are sufficient to fund operations for at least the next 12 months. During 2024 the company repurchased $250.0 million of stock under an accelerated share repurchase agreement, and it has $500.0 million remaining under a $750.0 million program authorized in February 2024.

The filing highlights concentration and execution risks. Partner A accounted for 41%d of 2024 total revenues and Partner B for 17%.

Revenue growth was driven largely by milestone timing and royalty growth from partner products such as DARZALEX SC and Phesgo. Key risks include reliance on partners' regulatory approvals and commercialization, single-source bulk rHuPH20 manufacturing, and an FDA Complete Response Letter received by Janssen in December 2024 for SC amivantamab.

Key Highlights

  1. Total revenues of $1,015,324 thousand in 2024, up from $829,253 thousand in 2023
  2. Royalties of $570,991 thousand, the largest revenue component, up from $447,865 thousand
  3. Net income of $444,091 thousand and diluted EPS of $3.43, compared with $281,594 thousand and $2.10 in 2023
  4. Cash, cash equivalents and marketable securities of $596.1 million, with management stating these are sufficient for at least the next 12 months
  5. Total convertible notes principal of $1,525.0 million, including $805.0 million due 2027 and $720.0 million due 2028
  6. Repurchased $250.0 million of common stock via an ASR in December 2024; $500.0 million remains under the February 2024 program
  7. Partner A accounted for 41% of total 2024 revenues, indicating significant customer concentration

Follow one dollar

Of each $1.00 of revenue in FY2024, Halozyme Therapeutics kept $0.44.

  1. Revenue$1.02B100.0%
  2. Cost of revenue−$159.4M15.7%
  3. Gross profit$855.9M84.3%
  4. Operating costs−$304.4M30.0%
  5. Operating income$551.5M54.3%
  6. Interest, other & tax−$107.4M10.6%
  7. Net income$444.1M43.7%
Computed from 10-KFY2024filed February 18, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2024 revenue went

$1.02B
  • Net income: $444.1M, 44% of revenue
  • Cost of revenue: $159.4M, 16% of revenue
  • SG&A: $154.3M, 15% of revenue
  • R&D: $79.0M, 7.8% of revenue
  • Other operating costs: $71.0M, 7.0% of revenue
  • Interest, other & tax: $107.4M, 11% of revenue

Kept 44% as net income

Full revenue history →

Financial Statements

FY2024 against FY2023

Line itemFY2024FY2023Change
Revenue$1.02B$829.25M+22.4%
Cost of Revenue$159.42M$192.36M−17.1%
Gross Profit$855.91M$636.89M+34.4%
R&D Expenses$79.05M$76.36M+3.5%
SG&A Expenses$154.34M$149.18M+3.5%
Operating Expenses$463.85M$491.68M−5.7%
Operating Income$551.48M$337.57M+63.4%
Net Income$444.09M$281.59M+57.7%
EPS (Basic)$3.50$2.13+64.3%
EPS (Diluted)$3.43$2.10+63.3%
Shares Outstanding (Basic)126.83M131.93M−3.9%
Shares Outstanding (Diluted)129.42M134.20M−3.6%

Frequently Asked Questions

  1. What drove the increase in revenue in 2024?

    Royalties rose to $570,991 thousand from $447,865 thousand, driven by sales uptake of DARZALEX SC by Janssen and Phesgo by Roche and the prior-year launch of VYVGART Hytrulo by argenx. Revenues under collaborative agreements rose to $140,841 thousand from $80,534 thousand, primarily due to the timing of milestones achieved. Product sales, net were nearly flat at $303,492 thousand versus $300,854 thousand, as proprietary product sales grew to $166,620 thousand while bulk rHuPH20 sales declined.

  2. How much debt does Halozyme carry and when does it mature?

    As of December 31, 2024, aggregate principal of convertible notes was $1,525.0 million: $805.0 million of 0.25% notes due March 1, 2027 and $720.0 million of 1.00% notes due August 15, 2028. The carrying amount of long-term debt was $1,505,798 thousand. The company also has a revolving credit facility of $575 million under its 2022 Credit Agreement, which was undrawn at year-end and matures November 30, 2026 unless extended.

  3. Is the company exposed to concentration risk among its partners?

    Yes. The filing reports that Partner A represented 41% of total 2024 revenues, Partner B 17%, and Partner C 8%. Accounts receivable at year-end were concentrated, with about 60% due from Janssen and Roche. The company also states that ENHANZE is its largest revenue driver, so adverse developments involving rHuPH20 or key collaborations could have a substantial impact.

  4. What are the main risks flagged for the rHuPH20 franchise?

    The filing notes that elevated anti-rHuPH20 antibody titers were detected in the HYQVIA registration trial and in a former partner's Phase 2 trial, though no adverse events were associated with them. It also states that the FDA delayed HYQVIA's approval until additional preclinical data were provided. Any future regulatory concerns about these antibodies could delay Hylenex commercialization, partner programs or additional ENHANZE collaborations.

  5. How does the company return capital to shareholders?

    The company has never paid dividends and intends to retain cash. It completed a $750.0 million three-year repurchase program in June 2024, repurchasing 19.1 million shares at an average price of $39.31. Under a new $750.0 million program authorized in February 2024, it entered a $250.0 million ASR in December 2024, taking initial delivery of 4.2 million shares, with $500.0 million remaining as of December 31, 2024.